Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer

M. Venturini, C. Bighin, S. Monfardini, F. Cappuzzo, N. Olmeo, A. Durando, F. Puglisi, O. Nicoletto, A. Lambiase, L. Del Mastro
  • Breast Cancer Research and Treatment, November 2005, Springer Science + Business Media
  • DOI: 10.1007/s10549-005-9030-x

The authors haven't finished explaining this publication. If you are the author, sign in to claim or explain your work.

Read Publication

The following have contributed to this page: Dr Federico Cappuzzo and Fabio Puglisi